Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead

Nuclear factor-kappa B (NF-kB) Inhibitors Therapeutics Pipeline Analysis, 2017 According to P&S Market Research

347, 5th Ave. #1402, United States - October 23, 2017 /MarketersMedia/ —

The study analyzed that the NF-kB inhibitors therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Nuclear factor-kappa B (NF-kB) is the transcription factor which is involved in the regulation of over 500 genes, that are responsible for cell proliferation, survival, invasion, metastasis, angiogenesis and inflammation. Therefore, development of therapeutics that acts as NF-kB inhibitors, can treat various diseases including cancer and chronic inflammation.

Request For Sample Pages: https://www.psmarketresearch.com/market-analysis/nf-kb-inhibitors-therapeutics-pipeline-analysis/report-sample

According to the research findings, most of the drug candidates in the NF-kB inhibitors therapeutics pipeline are being developed as small molecule using synthetic source.

According to the National Cancer Institute, the prevalence of cancer has been increasing at a very high rate. Therefore, companies are focusing on developing target specific and personalized medicine for the better treatment with reduced adverse events. Thus, NF-kB inhibitors therapeutics pipeline is likely to grow significantly, in the future, for the treatment of various diseases including cancer and chronic inflammation.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=nf-kb-inhibitors-therapeutics-pipeline-analysis

In May 2014, AnGes MG, Inc. and Shionogi & Co., Ltd. entered in a license agreement to co-develop NF-kB decoy oligodeoxynucleotide for the treatment of atopic dermatitis.

Some of the key players developing drugs as NF-kB inhibitors for the treatment of various indications include Alkermes Plc, Reata Pharmaceuticals, Inc., Incuron LLC, Catabasis Pharmaceuticals, Inc. and others.

NF-kB Inhibitors Therapeutics Pipeline Analysis

By Phase
By Molecule Type
By Route of Administration
By Company

Contact:
Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

Contact Info:
Name: Kundan Kumar
Organization: P&S Market Research

Source URL: https://marketersmedia.com/nuclear-factor-kappa-b-nf-kb-inhibitors-therapeutics-pipeline-projects-vast-growth-ahead/253390

For more information, please visit https://www.psmarketresearch.com/market-analysis/nf-kb-inhibitors-therapeutics-pipeline-analysis

Source: MarketersMedia

Release ID: 253390